All Dealmakers
Similar Dealmakers
Partner at Skadden Arps Slate Meagher & Flom
Financial Advisor
Boston
Deal Bio
Market Context
Awards
Back to top
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.
Expertise (63)
Key Relationships
Sort
Juno Therapeutics
Celgene Corporation
£5.86b
dealmakers
Kite Pharma
Gilead Sciences
£9.30b
Wework Companies
Softbank Group Corp
value n/a
Webroot
Carbonite
£477m
Clementia Pharmaceuticals
IPSEN
£995m
Nightstar Therapeutics
Biogen
£663m
Array Biopharma
Pfizer
£9.05b
Galapagos
£849m
Semma Therapeutics
Vertex Pharmaceuticals
£785m
Alder Biopharmaceuticals
Lundbeck As
£1.56b
Bioverativ
Sanofi
£7.85b
Achillion Pharmaceuticals
Alexion Pharmaceuticals
£732m
OPENTEXT
£1.11b
Arqule
Merck Kgaa
£2.05b
£3.47b
Legg Mason
Franklin Templeton Investments Corporation
£4.99b
Forty Seven
£3.82b
Stemline Therapeutics
Menarini Group
£541m
Portola Pharmaceuticals
£1.31b
Momenta Pharmaceuticals
Johnson & Johnson
£4.93b
Cersci Therapeutics
Acadia Pharmaceuticals
£717m
Akcea Therapeutics
Ionis Pharmaceuticals
£334m
Wework China
Trustbridge Partners
£157m
Urovant Sciences
Sumitovant Biopharma
£144m
Boston Dynamics
Hyundai Motor Group
£695m
National Holdings
B. Riley Financial
Gw Pharmaceuticals
Jazz Pharmaceuticals
£5.27b
Pandion Therapeutics
Merck & Co
Five Prime Therapeutics
Amgen
£1.36b
Bow Capital
£6.53b
STRONGBRIDGE
Xeris Pharmaceuticals
£188m
Constellation Pharmaceuticals
Morphosys
£1.20b
Translate Bio
£2.30b
Amicus Therapeutics (gene Therapy Business)
Arya Sciences Acquisition Corp Iv
£440m
Acceleron Pharma
£8.53b
Aspen Technology
Emerson Electric Co
£8.08b
DICERNA
Novo Nordisk
£2.45b
BOTTOMLINE
Thoma Bravo
£1.96b
Sierra Oncology
Glaxosmithkline
£1.52b
Antares Pharma
HALOZYME
£737m
Biohaven Pharmaceutical Holding Company
£9.42b
VIACYTE
£265m
Aerie Pharmaceuticals
Alcon
£650m
Cincor Pharma
Astrazeneca
£1.49b
Seagen
£35.70b
Prometheus Biosciences
£8.70b
Bellus Health
£1.61b
Iveric Bio
Astellas Pharma
£4.69b
Cti Biopharma
Swedish Orphan Biovitrum (sobi)
£1.35b
Intercept Pharmaceuticals
Alfasigma
£649m
Point Biopharma
Eli Lilly And Company
£1.15b
Mirati Therapeutics
Bristol Myers Squibb Company
£3.84b
ENGAGESMART
Vista Equity Partners
£3.29b
Cerevel Therapeutics
Abbvie
£6.89b
Ambrx
Novartis
£2.31b
Cymabay Therapeutics
£3.40b
Alpine Immune Sciences
£3.87b
INHIBRX
£1.34b
EYEBIOTECH
£2.35b
23andme
Anne Wojcicki
R1 Rcm
Towerbrook Capital Partners
£6.93b
G1 Therapeutics
Pharmacosmos Therapeutics
£318m